Tumor-educated platelets in myositis patients: screening for malignancies

Tumor-educated platelets in myositis patients: screening for malignancies - TEPs in myositis patients: malignancy screening

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50252

Enrollment

Registered

2021-10-18

Start date

2021-09-26

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer Myositis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patients with dermatomyositis (DM) and immune mediated necrotizing myopathy (IMNM) with or without a myositis specific antibody, with a known malignancy (out of a list of 16 malignancies). 2. Informed consent.

Exclusion criteria

Exclusion criteria: No informed consent Women who are pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame
blood platelet mRNA profile	—

Countries

Netherlands

Outcome results